Trials / Terminated
TerminatedNCT03140176
Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.
REAL-WORLD CLINICAL PATTERNS OF CARE AND OUTCOMES AMONG PATIENTS IN AFRICA MIDDLE EAST (AFME) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) RECEIVING SUNITINIB AS FIRST LINE THERAPY (OPTIMISE).
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 77 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
OPTIMISE is designed to provide knowledge regarding the use of Sunitinib as 1st line treatment and 2nd line treatment selected (Sunitinib-different sequence) with respect to efficacy outcomes, adverse events, and health related QoL in the real life setting.
Detailed description
OPTIMISE study objectives are dual and aim primarily to increase the knowledge regarding the outcomes from Sunitinib use on one hand; and outcomes from the combined Sunitinib-2nd line sequence on the other hand in real life clinical practice. This will be addressed in many countries across AfME and in individual country cohorts to understand specificities and differences in use and outcomes
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sunitinib | Sunitinib is an FDA approved targeted therapy for use as first line therapy for patients with metastatic renal cell carcinoma. |
Timeline
- Start date
- 2017-08-15
- Primary completion
- 2022-01-22
- Completion
- 2022-01-22
- First posted
- 2017-05-04
- Last updated
- 2024-05-10
- Results posted
- 2024-05-10
Locations
8 sites across 4 countries: Algeria, Egypt, Kuwait, Morocco
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03140176. Inclusion in this directory is not an endorsement.